BR112017020135A2 - compostos orgânicos - Google Patents
compostos orgânicosInfo
- Publication number
- BR112017020135A2 BR112017020135A2 BR112017020135A BR112017020135A BR112017020135A2 BR 112017020135 A2 BR112017020135 A2 BR 112017020135A2 BR 112017020135 A BR112017020135 A BR 112017020135A BR 112017020135 A BR112017020135 A BR 112017020135A BR 112017020135 A2 BR112017020135 A2 BR 112017020135A2
- Authority
- BR
- Brazil
- Prior art keywords
- organic compounds
- relates
- present
- methods
- phenylpropanamines
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- YERLRZHCJQXVGS-UHFFFAOYSA-N 1-phenyl-1-pyridin-2-yloxypropan-1-amine Chemical class C=1C=CC=CC=1C(N)(CC)OC1=CC=CC=N1 YERLRZHCJQXVGS-UHFFFAOYSA-N 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135915P | 2015-03-20 | 2015-03-20 | |
| PCT/US2016/023198 WO2016154027A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020135A2 true BR112017020135A2 (pt) | 2018-05-29 |
Family
ID=56977765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020135A BR112017020135A2 (pt) | 2015-03-20 | 2016-03-18 | compostos orgânicos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10188758B2 (https=) |
| EP (1) | EP3270920B1 (https=) |
| JP (1) | JP6726200B2 (https=) |
| KR (1) | KR20170129906A (https=) |
| CN (1) | CN107405339A (https=) |
| AU (1) | AU2016235483A1 (https=) |
| BR (1) | BR112017020135A2 (https=) |
| CA (1) | CA2978668A1 (https=) |
| ES (1) | ES2819833T3 (https=) |
| IL (1) | IL254320A0 (https=) |
| MX (1) | MX2017012022A (https=) |
| RU (1) | RU2017134796A (https=) |
| WO (1) | WO2016154027A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| JP2022506378A (ja) * | 2018-11-02 | 2022-01-17 | エステベ ファーマシューティカルズ，ソシエダッド アノニマ | 疼痛及び疼痛に関連する状態を処置するための新規なテトラヒドロピリミドジアゼピン及びテトラヒドロピリドジアゼピン化合物 |
| EP3873901A1 (en) * | 2018-11-02 | 2021-09-08 | Esteve Pharmaceuticals, S.A. | New alcoxyaminopyridine derivatives for treating pain and pain related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ313076A (en) * | 1995-07-24 | 1999-11-29 | Lilly Co Eli | Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders |
| EP1587781A1 (en) * | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| BRPI0510453A (pt) * | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| WO2007010082A1 (en) * | 2005-07-15 | 2007-01-25 | Fermion Oy | Process for preparing a 3-aryloxy-3-arylpropylamine |
| EP2066630A1 (en) * | 2006-08-23 | 2009-06-10 | Pfizer Products Incorporated | Piperidine derivatives |
| ES2553891T3 (es) * | 2007-06-04 | 2015-12-14 | Intra-Cellular Therapies, Inc. | Derivados de piridina como moduladores NET/SERT |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| US9352218B2 (en) | 2009-04-21 | 2016-05-31 | Nintendo Co., Ltd. | Game apparatus and computer-readable storage medium |
-
2016
- 2016-03-18 US US15/560,107 patent/US10188758B2/en active Active
- 2016-03-18 BR BR112017020135A patent/BR112017020135A2/pt not_active Application Discontinuation
- 2016-03-18 WO PCT/US2016/023198 patent/WO2016154027A1/en not_active Ceased
- 2016-03-18 CN CN201680014968.7A patent/CN107405339A/zh active Pending
- 2016-03-18 CA CA2978668A patent/CA2978668A1/en not_active Abandoned
- 2016-03-18 EP EP16769428.0A patent/EP3270920B1/en active Active
- 2016-03-18 KR KR1020177030305A patent/KR20170129906A/ko not_active Withdrawn
- 2016-03-18 MX MX2017012022A patent/MX2017012022A/es unknown
- 2016-03-18 ES ES16769428T patent/ES2819833T3/es active Active
- 2016-03-18 AU AU2016235483A patent/AU2016235483A1/en not_active Abandoned
- 2016-03-18 RU RU2017134796A patent/RU2017134796A/ru not_active Application Discontinuation
- 2016-03-18 JP JP2017549188A patent/JP6726200B2/ja active Active
-
2017
- 2017-09-04 IL IL254320A patent/IL254320A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2978668A1 (en) | 2016-09-29 |
| CN107405339A (zh) | 2017-11-28 |
| ES2819833T3 (es) | 2021-04-19 |
| US10188758B2 (en) | 2019-01-29 |
| EP3270920B1 (en) | 2020-06-17 |
| RU2017134796A (ru) | 2019-04-04 |
| EP3270920A4 (en) | 2018-10-24 |
| JP2018508556A (ja) | 2018-03-29 |
| MX2017012022A (es) | 2018-01-30 |
| WO2016154027A1 (en) | 2016-09-29 |
| JP6726200B2 (ja) | 2020-07-22 |
| AU2016235483A1 (en) | 2017-10-12 |
| IL254320A0 (en) | 2017-11-30 |
| EP3270920A1 (en) | 2018-01-24 |
| KR20170129906A (ko) | 2017-11-27 |
| US20180099060A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122740T1 (el) | Ευτηκτικα σκευασματα υδροχλωρικης κυκλοβενζαπρινης και μαννιτολης | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| MX2020008024A (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas. | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| EA201690372A1 (ru) | Азапиридоновые соединения и их применение | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| MX384800B (es) | Derivado de 3-desoxi y composiciones farmaceuticas del mismo. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX394123B (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos | |
| GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| BR112016024235A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| CY1123880T1 (el) | Καινοτομοι 5-ητ2 ανταγωνιστες | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
| IL269884B1 (en) | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | |
| BR112017020135A2 (pt) | compostos orgânicos | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112017000591A2 (pt) | antagonistas da neurocinina b na reprodução de peixes | |
| UY36123A (es) | Derivados de carboxamida | |
| EP3582759A4 (en) | BIOEQUIVALENT PHARMACEUTICAL COMPOSITION OF PRE-ORDIOXETINE HYDROBROMIDE | |
| BR112017024126B8 (pt) | Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |